MiMedx Group, Inc (MDXG): Price and Financial Metrics

MiMedx Group, Inc (MDXG): $8.01

0.08 (+1.01%)

POWR Rating

Component Grades








MDXG Price/Volume Stats

Current price $8.01 52-week high $8.60
Prev. close $7.93 52-week low $2.43
Day low $7.81 Volume 468,700
Day high $8.18 Avg. volume 670,482
50-day MA $6.92 Dividend yield N/A
200-day MA $6.12 Market Cap 932.18M

MDXG Stock Price Chart Interactive Chart >


  • MDXG scores best on the Growth dimension, with a Growth rank ahead of 99.94% of US stocks.
  • MDXG's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • MDXG ranks lowest in Momentum; there it ranks in the 10th percentile.

MDXG Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MDXG is 232.35 -- better than 99.9% of US stocks.
  • The price/operating cash flow metric for MIMEDX GROUP INC is higher than 96.54% of stocks in our set with a positive cash flow.
  • MDXG's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.71% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MIMEDX GROUP INC are EZFL, BIOL, VVOS, RDFN, and CAPL.
  • Visit MDXG's SEC page to see the company's official filings. To visit the company's web site, go to www.mimedx.com.

MDXG Valuation Summary

  • MDXG's price/sales ratio is 2.7; this is 28.95% lower than that of the median Healthcare stock.
  • Over the past 192 months, MDXG's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MDXG.

Stock Date P/S P/B P/E EV/EBIT
MDXG 2023-11-20 2.7 627.4 -328.0 183.8
MDXG 2023-11-17 2.7 617.7 -323.0 180.8
MDXG 2023-11-16 2.5 586.2 -306.5 171.2
MDXG 2023-11-15 2.5 577.5 -301.9 168.6
MDXG 2023-11-14 2.5 585.4 -306.1 171.0
MDXG 2023-11-13 2.3 539.0 -281.8 156.9

MDXG Growth Metrics

    The 3 year price growth rate now stands at -24.26%.
  • The 2 year price growth rate now stands at -24.26%.
  • The year over year net cashflow from operations growth rate now stands at 77.59%.
MDXG's revenue has moved up $19,607,000 over the prior 24 months.

The table below shows MDXG's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 267.841 -17.893 -36.777
2022-09-30 260.875 -15.501 -34.049
2022-06-30 256.26 -10.13 -27.866
2022-03-31 257.542 -5.526 -18.646
2021-12-31 258.615 -1.982 -16.421
2021-09-30 259.754 -9.017 -35.098

MDXG's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDXG has a Quality Grade of C, ranking ahead of 64.26% of graded US stocks.
  • MDXG's asset turnover comes in at 1.366 -- ranking 8th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows MDXG's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.366 0.833 -0.426
2021-06-30 1.316 0.833 -1.110
2021-03-31 1.302 0.842 -1.153
2020-12-31 1.369 0.842 -1.200
2017-09-30 1.597 0.881 0.532
2017-06-30 1.485 0.878 0.420

MDXG Price Target

For more insight on analysts targets of MDXG, see our MDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.17 Average Broker Recommendation 1.5 (Moderate Buy)

MiMedx Group, Inc (MDXG) Company Bio

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue.

MDXG Latest News Stream

Event/Time News Detail
Loading, please wait...

MDXG Latest Social Stream

Loading social stream, please wait...

View Full MDXG Social Stream

Latest MDXG News From Around the Web

Below are the latest news stories about MIMEDX GROUP INC that investors may wish to consider to help them evaluate MDXG as an investment opportunity.

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum Capital Group 14th Annual Alpha Select Conference Thursday, November 16, 2023Sheraton New York Times Square Hotel811 7th Avenue, W 53rd St New York, NY Mizuho Medical Device & Healthcare Services Summit 2023Wednesday, December 6, 2023Sofitel New York45 W 44th StNew

Yahoo | November 13, 2023

MIMEDX to Highlight Published Data at SAWC Fall

Company Will Sponsor Lunch Symposium on November 3, 2023MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV. In addition, the Company will participate in the conference’s exhibition at booth number 511. In the session, Drs. Mouawad, Tettelbach, and Wahab will review r

Yahoo | November 2, 2023

Loss-Making MiMedx Group, Inc. (NASDAQ:MDXG) Set To Breakeven

MiMedx Group, Inc. ( NASDAQ:MDXG ) is possibly approaching a major achievement in its business, so we would like to...

Yahoo | November 2, 2023

MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript

MiMedx Group, Inc. (MDXG)

Q3 2023 Earnings Call

October 30, 2023 4:30 PM ET

Company Participants

Matt Notarianni - Head, Investor Relations

Joseph H. Capper - Chief Executive Officer

Doug Rice - Chief Financial Officer

Conference Call Participants

Chase Knickerbocker - Craig-Hallum Group

Anthony Petrone - Mizuho Group

Carl Byrnes - Northland Capital Markets

Swayampakula Ramakanth - H.C. Wainwright

John Vandermosten - Zacks



Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter ‘23 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only...

SA Transcripts on Seeking Alpha | October 31, 2023

MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2023 Earnings Call Transcript

MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2023 Earnings Call Transcript October 30, 2023 MiMedx Group, Inc. beats earnings expectations. Reported EPS is $0.06, expectations were $0.04. Operator: Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter ‘23 Operating and Financial Results Conference Call. At this time, all participants are in a […]

Yahoo | October 31, 2023

Read More 'MDXG' Stories Here

MDXG Price Returns

1-mo 34.85%
3-mo -1.84%
6-mo 34.85%
1-year 156.73%
3-year 170.61%
5-year 940.26%
YTD 188.13%
2022 -53.97%
2021 33.04%
2020 19.79%
2019 323.46%
2018 -85.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!